Narrative synthesis of published literature
Trazodone and Falls Risk in Older Adults: What the Evidence Shows
A summary of why trazodone's sedating and blood-pressure-lowering effects are specifically studied as a falls-risk factor in older adults, and how this shapes dosing recommendations.
Published August 8, 2026. Reviewed by our editorial team on August 8, 2026.
Who was studied: Older adults (typically 65+) prescribed trazodone or other sedating antidepressants
Falls are a leading cause of injury in older adults, and medications that cause sedation or drop blood pressure on standing are consistently flagged in geriatric prescribing guidance as modifiable contributors to falls risk. Trazodone's pharmacology — antihistamine-driven sedation plus alpha-1 adrenergic blockade affecting blood pressure — places it squarely in this category.
This is part of why many prescribers start older adults on notably lower trazodone doses than they would for a younger adult, and increase more gradually, watching specifically for dizziness on standing and daytime sedation. It does not mean trazodone should be avoided in older adults altogether — it remains a commonly and often appropriately used medication in this population — but it does mean falls-risk-aware dosing matters more here than in younger, healthier patients.
Main result: Multiple lines of evidence — pharmacology, clinical observation, and geriatric prescribing guidance — consistently identify sedating medications with blood-pressure effects, including trazodone, as a modifiable falls-risk factor in older adults, supporting lower starting doses and slower titration in this population.
Limitations: Much of the available evidence comes from observational and pharmacological data rather than dedicated randomized trials specifically isolating trazodone's falls contribution from other factors common in older adults (multiple medications, frailty, mobility issues).
Not medical advice. This summary is educational and does not replace individualized guidance from your prescriber.